Impact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial

ISSN
2296-5262
2296-5270
Date Issued
2014
Author(s)
Mossner, Maximilian
Jann, J.-C
Launinger-Loersch, E.
Nowak, D.
Platzbecker, Uwe
Giagounidis, Aristoteles A. N.
Goetze, K.
Letsch, Anne
Schlenk, Richard F.
Kohlmann, A.
Haferlach, Torsten
Bug, G.
Luebbert, Michael
Ganser, Arnold
Nowak, V.
Pressler, Jovita
Oblaender, Julia
Fey, Stephanie
Mueller, N.
Metzgeroth, Georgia
Hofmann, W.-K
Germing, U.
Nolte, F.